Sarepta Therapeutics Inc (LTS:0L35)
$ 121.67 0 (0%) Market Cap: 11.61 Bil Enterprise Value: 11.80 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 82/100

Sarepta Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 09, 2020 / 08:30PM GMT
Release Date Price: $126.15 (-9.75%)
Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Hi, this is Marty Auster. I'm the lead smid-cap biotech analyst at Credit Suisse. Thanks for joining us at the 29th Annual Credit Suisse Health Care Conference. I've got Doug Ingram, CEO, along with some members of the Sarepta Therapeutics team. Very happy to have you here today, Doug.

I guess for the folks listening in, haven't gotten one yet, but I think this one might be different. If anybody has any questions they'd like me to work into this fireside chat, please send me an e-mail. It's [email protected], and I'm happy to try to work in some questions as they come in.

But with that, I would like to turn it over to Doug. Thanks again for joining us. And I guess I would just open with -- most of the questions we get on Sarepta over the last year or so have been around 9001, the micro-dystrophin gene therapy, but there's obviously a lot more going on at Sarepta and there's a bigger vision beyond just a single gene therapy program. So maybe give you a chance to kind of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot